| Literature DB >> 25859862 |
Vitor Oliveira Carvalho1, Guilherme Veiga Guimarães1, Marcelo Luiz Campos Vieira, Marcelo Luiz Campos-Vieira1, Aparecida Maria Catai1, Vagner Oliveira-Carvalho1, Silvia Moreira Ayub-Ferreira1, Edimar Alcides Bocchi1.
Abstract
OBJECTIVE: To establish the determinants of the peak VO2 in heart transplant recipients.Entities:
Mesh:
Year: 2015 PMID: 25859862 PMCID: PMC4389529 DOI: 10.5935/1678-9741.20140055
Source DB: PubMed Journal: Rev Bras Cir Cardiovasc
Characterization of study participants
| Variables | Number of patients (%), dose(mg/day) |
|---|---|
| Etiology: | |
| Chagas (%) | 45% |
| Non-Chagas (%) | 55% |
| Men (%) | 68% |
| Recipients age (years) | 48±15 |
| Donors age (years) | 31±11 |
| Donors weight (kg) | 76±9 |
| Recipients weight (kg) | 68±13 |
| Donors height (cm) | 176±7 |
| Recipients height (cm) | 166±10 |
| Ischemic time (min) | 206±115 |
| Recipients BMI (Kg/m2 ) | 25±4 |
| Donors BMI (Kg/m2 ) | 25±2 |
| Time following heart transplant (months) | 64±54 |
| Resting heart rate (bpm) | 82±12 |
| Recipients heart rate reserve (bpm) | 49±17 |
| % of age-predicted peak heart rate | 77±12 |
| % of heart rate drop in the second minute of recovery | 8±8 |
| Left atrium diameter | 44±10 |
| Cold ischemia time (min) | 207±115 |
| VE/VCO2 slope | 30±6 |
| Right ventricle diameter (mm) | 22±3 |
| Left ventricle diastolic diameter (mm) | 48±4 |
| Left ventricle ejection fraction (%) | 62±5 |
| E/E’ ratio | 6.8±2.3 |
| LF/HF | 6.9±8.9 |
| Medication: | |
| Cyclosporine | 71%, 174±58 mg/day |
| Diuretics | 8.3% |
| ACE inhibitors (enalapril) | 10%, 23±14 mg/day |
| Angiotensin receptor antagonist (losartan) | 10%, 62±31 mg/day |
| Corticosteroids (prednisone) | 30%, 5.2±3.4 mg/day |
| Azathioprine | 30%, 76±25 mg/day |
| Mycophenolate | 37%, 1096±422 mg/day |
| Tacrolimus | 25%, 7±4 mg/day |
| Sirolimus | 1.6%, 1 mg/day |
| Everolimus | 3.3%, 1±0.35 mg/day |
| Calcium channel blocker (diltiazem) | 58%, 126±71 mg/day |
| Ezetimibe | 1.6%, 10 mg/day |
| Simvastatin | 68.3%,11.4±4.4 mg/day |
| Hydralazine | 6.6%, 144±116 mg/day |
| Metformin | 6.6%,1700±00 mg/day |
| Fluoxetine | 3.3%, 32±11 mg/day |
| Gabapentin | 1.6%, 400 mg/day |
| Olanzapine | 5%, 10 mg/day |
| Topiramate | 3.3%, 125±106 mg/day |
| Bromazepam | 5%, 3 mg/day |
| Insulin | 7.5%, 69±53 mg/day |
BMI=Body mass index, ECA=Angiotensin conversor enzyme inhibitors. LF/HF=Low/high frequency domain in heart rate variability
Fig.1Patients flow throughout the study
| Abbreviations, acronyms & symbols | |
|---|---|
| BMI | Body mass index |
| BNP | B-type Natriuretic Peptide |
| DT | Deceleration time |
| ECA | Angiotensin conversor enzyme inhibitors |
| IVRT | Isovolumic relaxation time |
| LF/HF | Low/high frequency domain in heart rate variability |
| RRi | R-R intervals |
| VO2 | Oxygen consumption |
| Authors’ roles & responsibilities | |
|---|---|
| VOC | Analysis and/or interpretation of data, statistical analysis, final approval of the manuscript, conception and design of the study, implementation of operations and/or experiments, manuscript writing or critical review of its content |
| GVG | Analysis and/or interpretation of data, final approval of the manuscript, design and study design, performance of operations and/or experiments |
| MLCV | Analysis and/or interpretation of data, final approval of the manuscript, current operations and/or experiments, manuscript writing or critical review of its content |
| AMC | analysis and/or interpretation of data, final approval of the manuscript, current operations and/or experiments, manuscript writing or critical review of its content |
| VOC | Analysis and/or interpretation of data, final approval of the manuscript, design and study design, performance of operations and/or experiments, manuscript writing or critical review of its content |
| SMAF | Analysis and/or interpretation of data, final approval of the manuscript, current operations and/or experiments |
| EAB | Analysis and/or interpretation of data, final approval of the manuscript, design and study design, performance of operations and/or experiments, manuscript writing or critical review of its content. |